Department of Toxicology, Second Military Medical University, Shanghai, China.
Drug Chem Toxicol. 2010;33(1):103-10. doi: 10.3109/01480540903196808.
It is reported that dehydrocavidine (DC), the main component of a traditional Chinese medicine, Yanhuanglian (YHL), can protect hepatic tissue against HBV and HAV impairment. As part of a safety evaluation on YHL-DC for use in the treatment of HBV, the present study evaluated the potential genotoxicity of YHL-DC by using the standard battery of tests (i.e., bacterial reverse mutation, chromosomal aberrations, and mouse micronucleus assays) recommended by the State Food and Drug Administration of China. The results showed that YHL-DC was not genotoxic under the conditions of the reverse mutation, chromosomal aberrations, and mouse micronucleus assay conditions. The anticipated clinical dose should be smaller than the doses used in the genotoxicity assays. With confirmation from further toxicity studies, YHL-DC would hopefully prove to be a useful anti-HBV agent.
据报道，中药炎黄连的主要成分脱水穿心莲内酯（DC）可保护肝组织免受 HBV 和 HAV 的损害。作为炎黄连-DC 用于治疗 HBV 的安全性评价的一部分，本研究通过中国国家食品药品监督管理局推荐的标准测试组合（即细菌回复突变、染色体畸变和小鼠微核试验）评估了炎黄连-DC 的潜在遗传毒性。结果表明，在回复突变、染色体畸变和小鼠微核试验条件下，炎黄连-DC 没有遗传毒性。预期的临床剂量应小于遗传毒性试验中使用的剂量。通过进一步的毒性研究证实，炎黄连-DC 有望成为一种有用的抗 HBV 药物。
